What are the recommended dosing, administration procedure, contraindications, and rescue medication for regadenoson used as a pharmacologic stress agent for myocardial perfusion imaging?

Regadenoson for Myocardial Perfusion Imaging

Administer regadenoson as a fixed 0.4 mg (5 mL) intravenous bolus over 10 seconds, followed immediately by a 5 mL saline flush, with the radionuclide injected 10-20 seconds after the flush. 1

Dosing and Administration Protocol

Standard Dose

• Fixed dose: 0.4 mg in 5 mL solution (no weight-based adjustment required) 2, 1
• Inject over 10 seconds into a peripheral vein using ≥22 gauge catheter 1
• Follow immediately with 5 mL saline flush 1
• Administer radionuclide 10-20 seconds after saline flush 2, 1
• Optimal imaging window: 2-4 minutes after drug infusion 2

Pre-procedure Requirements

Patients must avoid all methylxanthine products for ≥12 hours before testing, including:

• Caffeinated coffee, tea, beverages
• Caffeine-containing medications
• Aminophylline and theophylline 1

Key Advantages

Regadenoson simplifies workflow compared to adenosine or dipyridamole because it requires no infusion pump—administered by hand-held syringe 2. This makes it particularly useful during viral pandemics or when minimizing staff-patient contact time 3.

Contraindications

Absolute contraindications 1:

• Second- or third-degree AV block
• Sinus node dysfunction
• Exception: Patients with functioning artificial pacemaker may receive regadenoson

Relative contraindications/high-risk situations 1:

• Acute myocardial ischemia or unstable angina
• Cardiovascular instability
• Severe hypotension (SBP <90 mmHg)
• Recent MI (<2 days)
• Uncontrolled heart failure
• Severe COPD or acute bronchospasm (though regadenoson is preferred over adenosine in mild-moderate reactive airway disease) 4

Mechanism and Clinical Context

Regadenoson is a selective A2A adenosine receptor agonist that induces coronary vasodilation while avoiding or reducing undesirable A1, A2B, and A3 receptor effects (dyspnea, bronchospasm, headache, flushing) 2. It produces ischemia through horizontal steal (with coronary collaterals) and vertical steal (with critical stenosis) 2.

When to use regadenoson:

• Patients unable to exercise adequately 1
• Preferred over exercise stress during viral pandemics (no aerosol generation) 3
• Patients with left bundle branch block or paced rhythm (vasodilators preferred over exercise or dobutamine) 5
• Alternative to adenosine infusion when simplified workflow desired 3

Adverse Effects and Monitoring

Common Side Effects (≥5%)

• Dyspnea (64.2% in one large series) 6
• Headache (20-21%) 6, 7
• Flushing (20%) 6
• Chest discomfort/pain
• Dizziness
• Nausea 1

Most adverse effects are mild, self-limiting, and resolve without intervention 8.

Serious Adverse Events (Rare)

Cardiac complications 1, 9:

• Fatal and nonfatal MI, ventricular arrhythmias, cardiac arrest have occurred
• AV block: First-degree (3%), transient second-degree, third-degree heart block and asystole reported post-marketing
• New-onset or recurrent atrial fibrillation/flutter with rapid ventricular response
• Hypotension (7% with >35 mmHg SBP drop)
• Hypertension (particularly with low-level exercise)

Other serious events 1:

• Anaphylaxis, angioedema
• Seizures (new-onset or recurrent)
• Cerebrovascular accidents (hemorrhagic and ischemic strokes)
• Bronchoconstriction (though less than adenosine)

Hemodynamic Changes

Expect mean heart rate increase from ~70 to ~95 bpm and systolic BP drop of ~5-6 mmHg, both typically normalizing by 60 minutes 6, 7.

Rescue Medication: Aminophylline

If serious reactions occur, administer aminophylline (adenosine antagonist) to reverse regadenoson's effects 1:

Aminophylline Dosing

• Start with 70 mg IV over 1 minute
• Maximum dose: 240 mg over 3 minutes as slow bolus
• Avoid rapid injection—aminophylline is potentially arrhythmogenic 2

Important Caveats

• Do NOT use methylxanthines in patients who experience seizures with regadenoson 1
• Aminophylline may be effective even with late administration in end-stage renal disease patients (regadenoson has prolonged effect in ESRD) 10
• Unlike adenosine (half-life seconds), regadenoson effects may persist, making aminophylline availability crucial

Safety Requirements

Before administering regadenoson 1:

• Cardiac resuscitation equipment and trained staff must be immediately available
• Have aminophylline readily accessible
• Ensure ability to manage bronchospasm, arrhythmias, anaphylaxis
• Monitor vital signs and ECG during and after administration

Special Populations

COPD/Asthma patients: Regadenoson is safer than adenosine due to A2A selectivity, though bronchospasm remains possible. In one series of 508 COPD/asthma patients, no bronchospasms occurred 6. Resuscitative measures should still be available 1.

End-stage renal disease: Regadenoson may have prolonged pharmacodynamic effects; late aminophylline administration may be necessary 10.

Paced patients: Regadenoson can be used in patients with functioning pacemakers 1.

Clinical Pearls

• Regadenoson is more expensive than other vasodilators but the fixed bolus dose and simplified administration justify its use 2
• Adhere strictly to the 10-second injection time—longer injections may increase duration and magnitude of coronary blood flow 1
• Automatic BP cuffs minimize staff-patient contact 3
• For adenosine comparison: adenosine requires infusion pump at 140-210 μg/kg/min over 6 minutes with stepwise increments 2
• Regadenoson has comparable efficacy to adenosine with fewer side effects and greater convenience 8, 4